Propel: A Randomized, Phase Ill Trial Evaluating The Efficacy And Safety Of Olaparib Combined With Abiraterone As First-Line Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

Noel W. Clarke,Andrew J. Armstrong,Antoine Thiery-Vuillemin,Mototsugu Oya,Dingwei Ye,Joaquin Mateo,Carsten Dietrich Goessl,Jinyu Kang,Sherry Liu,Fred Saad

JOURNAL OF CLINICAL ONCOLOGY（2019）

引用 22|浏览12

暂无评分

摘要

TPS340Background: A Phase II trial showed olaparib (tablets, 300 mg bid) in combination with abiraterone (1000 mg od plus prednisone/prednisolone 5 mg bid) significantly prolonged radiologic progre...

查看译文

关键词

Metastatic Prostate Cancer,Proton Therapy,Olaparib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要